Seqens Seqens

X
[{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EraCal Therapeutics Enters into Research Collaboration with Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Peptide","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eracal Therapeutics"},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$255.0 million","upfrontCash":"Undisclosed","newsHeadline":"EraCal Therapeutics Enters into a Collaboration and License Agreement with Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Eracal Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Novo Nordisk has obtained all exclusive rights to develop and commercialize EraCal’s oral small molecule asset to control appetite and body weight with an eye toward treating obesity.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: $255.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 23, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the joint research plan, EraCal and Novo Nordisk will investigate novel molecules for their potential as anti-obesity pharmacotherapy. This will be done in zebrafish larvae, an emerging vertebrate drug discovery platform.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Peptide

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY